ReviewEuropean journal of rheumatology2016
Viral hepatitis screening guideline before biological drug use in rheumatic patients.
Review in European journal of rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis.Rheumatology international · 2019Guideline
- Current perspective on infections and mitigation strategies in primary systemic vasculitis.Current rheumatology reports · 2024Review
- Improving Hepatitis B Screening Prior to Rituximab: A Quality Improvement Project.Children (Basel, Switzerland) · 2023Article
- Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).European journal of pediatrics · 2022Review
- A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare.Open forum infectious diseases · 2021Article
- Infectious Complications in Autoimmune Hemolytic Anemia.Journal of clinical medicine · 2021Review
- Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy.Microorganisms · 2020Article
- Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.Joint Commission journal on quality and patient safety · 2019Article
- Article
- Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.Biologics : targets & therapy · 2018Review
- Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases.International journal of rheumatology · 2018Review
- Vaccination recommendations for adult patients with rheumatic diseases.European journal of rheumatology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary. This guideline covers pre-treatment screening and follow-up recommendations, if required, with respect to viral hepatitides in rheumatology patients who are planned to be given biological drugs. Although this guideline is prepared for biological disease-modifying antirheumatic drugs (DMARDs), it is recommended to be used also for target-oriented DMARDS and medium-high dose corticosteroids (>7.5 mg prednisolone/day equivalent). It should be considered that the reactivation risk is higher when more than one immunosuppressive drug is used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.